Senseonics - SENS STOCK NEWS

Senseonics Holdings, Inc. (NYSE American: SENS) announced its participation in the virtual H.C. Wainwright Global Life Sciences Conference on March 9, 2021. Management will engage in one-on-one meetings and a presentation webcast will be available at 7:00am ET on the same day. The webcast can be accessed via the Investor Relations section of their website. Senseonics is dedicated to developing innovative continuous glucose monitoring systems aimed at improving the quality of life for diabetes patients, featuring their Eversense® and Eversense® XL products.

Senseonics Holdings, Inc. (NYSE-American: SENS) is set to release its fourth quarter and full year 2020 financial results after the market closes on March 4, 2021. A conference call will follow at 4:30 p.m. ET to discuss these results, available via a webcast on the company's website. Senseonics specializes in implantable continuous glucose monitoring systems for diabetes management, including the Eversense systems that offer real-time glucose data to users.

Senseonics Holdings, Inc. (NYSE American: SENS) announced its participation in the virtual SVB Leerink Global Healthcare Conference on February 25, 2021, at 12:00 pm ET. The presentation will be accessible through the company's website under the 'Investor Relations' section. Senseonics specializes in developing long-term, implantable continuous glucose monitoring systems for diabetes patients, with products like Eversense® and Eversense® XL that provide timely glucose data directly to users' smartphones.

Senseonics Holdings, Inc. (NYSE American: SENS) announces that Ascensia Diabetes Care has commenced sales and marketing of the Eversense® XL CGM system in key European markets, enhancing their strategic partnership initiated in August 2020. The Eversense XL offers continuous glucose readings for up to 180 days with a single sensor. Ascensia will distribute the product in Germany, Italy, The Netherlands, Poland, Spain, and Switzerland, building on their existing support for the original Eversense® CGM system in the US. This collaboration aims to improve diabetes management for patients across Europe.

Senseonics Holdings, Inc. (SENS) announced the closing of a public offering of 59,740,259 shares of common stock on January 26, 2021. The offering was priced at $1.925 per share, generating approximately $115 million in gross proceeds. Funds will be utilized for general corporate purposes, including product development and regulatory approval for its 365-day continuous glucose monitoring system. The offering's completion allows Senseonics to fund operations until cash flow breakeven, based on current projections.

Senseonics Holdings, Inc. (NYSE American: SENS) announced an increased stock offering, purchasing 51,948,052 shares at $1.925 each due to strong demand. The offering, set to close around January 26, 2021, aims to raise approximately $100 million, subject to fees and expenses. The funds will support product development, regulatory approval, and commercialization efforts for its continuous glucose monitoring system in collaboration with Ascensia Diabetes Care. The offering is facilitated by H.C. Wainwright & Co. as the sole book-running manager.

Senseonics Holdings has entered into an underwriting agreement with H.C. Wainwright & Co. for a public stock offering of 25,974,026 shares at $1.925 each. The offering aims to close around January 26, 2021, pending customary conditions. Gross proceeds are estimated at $50 million, intended for corporate purposes, product development, and capital expenditures. An additional 3,896,103 shares may be offered under a 30-day option. The shares will be sold under an effective SEC registration statement.

Senseonics Holdings, Inc. (NYSE American: SENS) announced that EmblemHealth is now covering the Eversense® Continuous Glucose Monitoring (CGM) System, effective immediately, expanding access to around 2.9 million residents in New York, New Jersey, and Connecticut. This addition highlights the growing recognition among payers of CGM as a standard care for insulin-dependent diabetes management. The Eversense system features an implantable sensor and smart transmitter that enhances glucose monitoring. Improved coverage may aid in achieving better health outcomes for patients.

Senseonics Holdings, Inc. (NYSE American: SENS) has announced a registered direct offering of 40,000,000 shares of common stock at $1.25 per share, expected to raise $50.0 million before expenses. The offering is managed by H.C. Wainwright & Co. and is slated to close on or about January 21, 2021. The net proceeds will be allocated for general corporate purposes. The shares are being offered under a shelf registration statement filed with the SEC, ensuring compliance with regulatory requirements.